General Announcement::Press Release

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
18-Sep-2025 19:18:34
Status
New
Announcement Sub Title
Press Release
Announcement Reference
SG250918OTHRQM9C
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
18/09/2025 16:45:00
Description (Please provide a detailed description of the event in the box below)
Biocon Biologics Yesafili (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases

Attachments

BBL_PR_SGX_Yesafili_18092025.pdf
Total size =483K